Celebrating Chinese Doctor’s Day!
On August 19th, we honor the incredible dedication and compassion of doctors who work tirelessly to safeguard our health. Let's take a moment to appreciate their unwavering commitment to preserving…
Building a Health Defense Line, Focusing on China Anemia Day on August 18th: Caring for the Source of Life, Starting with Understanding Anemia
In the vast river of life, blood flows like an unceasing stream, nourishing every inch of land and supporting the vitality and vigor of every life. Anemia, a seemingly inconspicuous…
Cutting-edge Bi-monthly: July Literature Digest (Part 1)
Introduction: In this era of information explosion, how can one quickly access the latest developments in the field? Here, we select the latest literature in the field every month, focusing…
Dr. Zefei Jiang: Highlights, Innovations, and Reflections | 2024 Breast Cancer Summer Forum · Northern Salon
Editor's Note: On July 27-28, 2024, the "2024 Breast Cancer Summer Forum · Northern Salon" was grandly held at Beijing Shougang Park. The conference upheld the philosophy of "learning and…
ESMO 2024丨Key Research in Hematological Malignancies (Mini oral)
The 2024 European Society for Medical Oncology (ESMO) Annual Congress will take place from September 13th to 17th in Barcelona, Spain. As an annual celebration in the field of oncology,…
Dr. Nicolaus Kroger: New Perspectives on Myelofibrosis Treatment – Focusing on Post-Transplant Management and Minimal Residual Disease Monitoring
In the field of myelofibrosis treatment, allogeneic hematopoietic stem cell transplantation (allo-HSCT) serves as a curative approach, and the optimization of related strategies is particularly crucial. Recently, at the 12th…
Advancing Early-Stage Breast Cancer Monitoring with ctDNA Structural Variant Detection
A recent study published in Clinical Cancer Research (Jan 9, 2025) highlights the potential of structural variant (SV)-based circulating tumor DNA (ctDNA) detection in early-stage breast cancer (EBC). Unlike traditional…
Phase 3 EMBER-3 Trial: Imlunestrant in Advanced Breast Cancer
A study published in NEJM on December 11, 2024, led by Komal L. Jhaveri and colleagues, evaluated Imlunestrant, a next-generation oral selective estrogen receptor (ER) degrader, in ER-positive, HER2-negative advanced…
Three First-Line Strategies for EGFR-Mutant NSCLC: How to Choose the Right One?
Clinicians and researchers continue to seek targeted treatment strategies for EGFR-mutant non-small cell lung cancer (NSCLC), with an increasing number of clinical trials evaluating combination therapies. Two recent high-profile studies, the FLAURA-2 and MARIPOSA trials, have led to the FDA approval of new first-line treatment options for EGFR-mutant NSCLC in 2024.
Honoring Dr. Abdullah Tarik Aslan and His Research on Antibiotic-Associated Nephrotoxicity
Dr. Abdullah Tarik Aslan, alongside his colleagues, has led an important multinational, multicenter cohort study investigating the risk of acute kidney injury (AKI) in patients receiving piperacillin-tazobactam (TZP) with either vancomycin (VAN) or teicoplanin (TEI).